

## CLINIC RESEARCH

# Heart failure complicating myocardial infarction. A report of the Peruvian Registry of ST-elevation myocardial infarction (PERSTEMI)



Manuel Chacón-Díaz\*, Ofelia Araoz-Tarco, Walter Alarco-León,  
Oscar Aguirre-Zurita, Maritza Rosales-Vidal, Patricia Rebaza-Miyasato

Servicio de Cardiología Clínica Instituto Nacional Cardiovascular "Carlos Alberto Peschiera Carrillo" – INCOR, Lima, Peru

Received 11 January 2018; accepted 25 March 2018

### KEYWORDS

Heart failure;  
Myocardial infarction;  
Reperfusion;  
Mortality;  
PERSTEMI;  
Peru

### Abstract

**Objectives:** The aim of this study is to determine the incidence, associated factors, and 30-day mortality of patients with heart failure (HF) after ST elevation myocardial infarction (STEMI) in Peru.

**Methods:** Observational, cohort, multicentre study was conducted at the national level on patients enrolled in the Peruvian registry of STEMI, excluding patients with a history of HF. A comparison was made with the epidemiological characteristics, treatment, and 30 day-outcome of patients with (Group 1) and without (Group 2) heart failure after infarction.

**Results:** Of the 388 patients studied, 48.7% had symptoms of HF, or a left ventricular ejection fraction <40% after infarction (Group 1). Age > 75 years, anterior wall infarction, and the absence of electrocardiographic signs of reperfusion were the factors related to a higher incidence of HF. The hospital mortality in Group 1 was 20.6%, and the independent factors related to higher mortality were age > 75 years, and the absence of electrocardiographic signs of reperfusion.

**Conclusions:** Heart failure complicates almost 50% of patients with STEMI, and is associated with higher hospital and 30-day mortality. Age greater than 75 years and the absence of negative T waves in the post-reperfusion ECG are independent factors for a higher incidence of HF and 30-day mortality.

© 2018 Instituto Nacional de Cardiología Ignacio Chávez. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\* Corresponding author: Jirón coronel Félix Zegarra 417, Jesús María, Lima, Peru. Tel.: +051 1 4111560; mobile: 051 1 989433241.  
E-mail address: [manuelchacon03@yahoo.es](mailto:manuelchacon03@yahoo.es) (M. Chacón-Díaz).

**PALABRAS CLAVE**

Insuficiencia  
cardíaca;  
Infarto de miocardio;  
Reperusión;  
Mortalidad;  
PERSTEMI;  
Perú

## Insuficiencia cardíaca complicando el infarto de miocardio. Un reporte de Peruvian Registry of ST-elevation Myocardial Infarction (PERSTEMI)

**Resumen**

**Objetivos:** Se desea saber la incidencia, los factores asociados y la mortalidad a 30 días de los pacientes con insuficiencia cardíaca (IC) postinfarto de miocardio con elevación del segmento ST (IMCEST) en Perú.

**Métodos:** Estudio observacional, de cohortes, multicéntrico a nivel nacional, de pacientes enrolados en el registro peruano de IMCEST, excluyendo los pacientes con antecedente de IC. Se compararon las características epidemiológicas, tratamiento y evolución a 30 días de los pacientes con (grupo 1) y sin (grupo 2) IC postinfarto.

**Resultados:** De 388 pacientes se encontró un 48.7% con síntomas de IC o fracción de eyección de ventrículo izquierdo < 40% postinfarto (grupo 1). La edad > 75 años, el infarto de pared anterior y la ausencia de signos electrocardiográficos de reperusión fueron los factores relacionados a mayor incidencia de IC. La mortalidad intrahospitalaria en el grupo 1 fue del 20.6% y los factores independientes relacionados a mayor mortalidad fueron la edad > 75 años y la ausencia de signos electrocardiográficos de reperusión.

**Conclusiones:** La IC complica casi al 50% de pacientes con IMCEST y está asociada a mayor mortalidad intrahospitalaria y a 30 días. La edad > 75 años y la ausencia de ondas T negativas en el electrocardiograma posreperusión son factores independientes de mayor incidencia de IC y de mortalidad a 30 días.

© 2018 Instituto Nacional de Cardiología Ignacio Chávez. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Introduction**

Heart failure (HF) is a clinical entity produced by several etiological agents, being the coronary heart disease the most frequent cause worldwide (70%).<sup>1</sup> Symptomatic HF that complicates myocardial infarction (MI) occurs in approximately 15–25% of patients<sup>2–6</sup> and is associated with an in-hospital mortality range of 15–40%.<sup>2–5</sup>

The prognosis after a MI will depend on the degree of left ventricular systolic dysfunction (LVSD) with or without symptomatic HF, the presence of recurrent ischemia and the degree of progression of coronary disease;<sup>7</sup> being the LVSD the strongest predictor of mortality.<sup>8</sup> This dysfunction has as substrate in the acute phase: the loss of myocardial cells and ventricular remodeling, besides the myocardial “stunning” and valve dysfunction.<sup>8</sup>

The Killip score has been used to predict higher mortality after infarction<sup>9,10</sup> and its simple applicability at the time of admission of the patient with MI makes this score an important prognostic tool.

Due to the high morbidity and mortality of HF, we want to evaluate its incidence in the context of ST-segment elevation myocardial infarction (STEMI), its epidemiological characteristics and factors associated with its presentation, as well as identify predictors of in-hospital mortality.

**Methods**

The PERSTEMI registry<sup>11</sup> is a prospective, multicenter, observational registry of patients with STEMI, where a total of 396 patients were enrolled from February 2016 to February 2017 in the most important cities of Peru. For this report,

patients with a history of heart failure prior to admission were excluded.

Patients were classified according to the presence (group 1), or absence (group 2) of heart failure (HF) which was defined by:

- Symptoms and signs compatible with heart failure according to Framingham criteria<sup>12</sup> during hospitalization, or;
- Killip Classification >1 on admission or during hospitalization, or;
- Left ventricular ejection fraction (LVEF) less than or equal to 40% during hospitalization.

Data were collected about the current clinical history, cardiovascular past history and risk factors, as well as electrocardiogram (ECG) characteristics, in-hospital management, reperfusion therapy, adverse events during hospitalization and medication at hospital discharge in both groups.

The LVEF was evaluated by transthoracic echocardiography between 24 and 48 h after admission; the method used for its assessment was the Simpson biplane method. Follow-up was done by telephone or by evaluating the records in the clinical history.

**Statistic analysis**

Qualitative variables are presented in frequencies and percentages and continuous variables as medians and interquartile range, except age (mean and standard deviation). The comparison between the groups was carried out

with the chi-square test and student's *t* test for discrete and continuous variables, respectively. A value of  $p < 0.05$  was considered statistically significant. Multiple logistic regression analysis was performed for the evaluation of variables associated with a greater possibility of developing heart failure due to MI and for the evaluation of in-hospital mortality in the group with HF. The 30-day survival in both study groups was evaluated by Cox regression and plotted with Kaplan Meyer curves. All information was tabulated in Stata 14.0 program.

## Results

A total of 388 patients were evaluated. One hundred and eighty-nine patients (48.7%) met the pre-established criteria for heart failure after MI (group 1) and 199 patients (51.3%) without HF entered to group 2.

One hundred patients (26.03%) had HF symptoms during hospitalization, 130 patients (33.5%) arrived to emergency wards with symptoms of HF (KK II to IV) and 117 patients (31.03%) had an echocardiographic report with LVEF  $< 40\%$ .

There were no differences according to sex, or the presence of traditional coronary risk factors (hypertension, diabetes mellitus, dyslipidemia, renal failure) between the two groups (Table 1); but the average age was significantly higher in the population with HF (66.9 versus 62.9 years,  $p = 0.002$ ).

In the group 1, 120 patients (63.4%) had LVEF  $\leq 40\%$ , and 36.6% of cases with symptomatic HF had LVEF  $> 40\%$ . It was also found that 31 patients (16.4%) had only LVEF  $\leq 40\%$  without symptoms (left ventricular asymptomatic dysfunction). Six patients (3.2%) of group 1 had right ventricle infarction.

A 31.2% of patients in the group 1 were admitted to emergency without symptoms of HF (Killip I), on this group 23.7% were older than 75 years and 74.5% had anterior location's MI (OR 3.8, CI: 2–7.3,  $p = 0.000$ ).

A high percentage of patients in group 1 were older than 75 years, the infarction involved the anterior wall of the left ventricle, had higher troponin values and did not have negative T waves after reperfusion in the EKG compared with patients without HF (Tables 1 and 2).

The median LVEF of group 1 was 40% (IQR 35–45%) and in group 2 was 50% (IQR 45–56%) ( $p = 0.000$ ), more cases of severe mitral regurgitation were observed in group 1 (4.8% versus 1.05%,  $p = 0.006$ ).

A 50.7% of patients of group 1 and 58.2% of group 2 had coronary angiograms for reperfusion treatment of STEMI ( $p = 0.138$ ). Among patients who underwent coronary angiography, there was a tendency to lower TIMI 3 coronary flow post intervention in group 1 than in group 2 (75.5% versus 88.7%,  $p = 0.060$ ). We did not find differences in the time of ischemia to reperfusion, or in the reperfusion strategy (fibrinolysis versus angioplasty) between the 2 groups. Pharmacoinvasive strategy was used in 25 patients in group 1 (26.04%) and in 26 patients of group 2 (22.41%).

In patients undergoing PCI (primary or pharmacoinvasive) we found that the anterior descending coronary artery was the infarct related artery (IRA) in 73.9% of patients in group 1 and in 42.2% in group 2; the right coronary artery was the IRA in 14.5% of patients in group 1 and 49.1% in group 2 ( $p = 0.000$ ). More than one coronary artery with

severe obstruction was found in 55.8% of patients in group 1 and 53.4% in group 2 ( $p = 0.734$ ). Another PCI besides of the IRA, were done in 33.7% of cases in group 1 and 35.5% of cases in group 2 ( $p = 0.809$ ) mainly deferred before discharge from the hospital (65% in group 1 and 90% in group 2). Drug eluting stent was used in 62.5% of cases in group 1 and 58.6% in group 2 ( $p = 0.701$ ).

Regarding the in-hospital treatment, there was a greater percentage of inotropic use, invasive ventilation and intra-aortic balloon counterpulsation (IABP) in group 1 (Table 3), as well as greater use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blocker (ARBs), diuretics and spironolactone at discharge, there was no difference in the percentage of use of beta blockers. In patients with LVEF  $< 40\%$ , beta blockers were used in 85% of cases, ACEI/ARBs in 82.9% and spironolactone in 45.4%.

Hospital stay was slightly longer in group 1 (7 days, IQR: 4–12 days) than in group 2 (6 days, IQR: 5–8 days)  $p = 0.000$ .

In-hospital cardiovascular mortality was 20.6% in the group 1 (39 patients) and 0.5% in group 2 ( $p = 0.000$ ). Mortality in patients with symptomatic HF was 33% versus 2.1% in asymptomatic patients ( $p < 0.0001$ ). The most frequent cause of death in group 1 was cardiogenic shock (74.3%) followed by arrhythmic death (15.4%). In patients with cardiogenic shock: 16% was due to mechanical complication and in 73.8% of cases the EKG post reperfusion showed persistent T positive waves in infarct related leads reflecting non myocardial cell reperfusion in spite of good angiographic results.

The rate of re-infarction, ventricular tachycardia or ventricular fibrillation and severe pericardial effusion was higher in group 1 than in group 2 (4.2% versus 0.5%,  $p = 0.015$ , 12% versus 1.5%,  $p = 0.000$  and 6.8% versus 1.5%,  $p = 0.008$  respectively).

Patients of group 1 had more in-hospital mortality (OR: 1.45; 95% CI: 1.15–1.82,  $p < 0.001$ ) and worst 30-day survival (Fig. 1).

The factors related to higher mortality in patients of group 1 in the first 30 days from admission are shown in Table 4.

According to Killip classification on admission, in-hospital mortality was 3.1, 17.8, 27.2 and 61.1% in Killip I, II, III and IV respectively.

The univariate analysis of therapies administered in the intensive care unit, showed that only the use of noradrenaline was related to higher mortality in group 1 (OR 6.2, CI: 1.3–28,  $p = 0.018$ ), although it is true that the need for invasive mechanical ventilation, IABP and inotropic use was associated with higher mortality, these associations were not statistically significant (OR 2.2, CI: 0.5–9.4,  $p = 0.281$ , OR 6, CI: 0.6–59.7,  $p = 0.124$  and OR 4.3, CI: 0.8–21.9,  $p = 0.079$  respectively).

## Discussion

In this study, we found an incidence of HF post STEMI of 48.7%, higher than that found by the FAST-MI researchers; who with the same criteria for defining the group with HF, found an incidence of 37.5%,<sup>13</sup> this difference may due in

**Table 1** Characteristics of the patients.

	Group 1 (n=189)		Group 2 (n=199)		p
	n	%	n	%	
Female sex	40	21.1	41	20.6	0.892
Age (years), (mean $\pm$ SD)		66.9 $\pm$ 0.9		62.9 $\pm$ 0.8	0.002
Older than 75 years	61	32.2	36	18.1	0.001
Arterial hypertension	108	57.1	106	53.2	0.443
Type 2 diabetes	44	23.2	49	24.6	0.757
Dyslipidemia	65	34.3	67	33.6	0.881
Chronic kidney disease	6	3.1	5	2.5	0.695
SBP (mmHg)*		120 (100–130)		130 (110–140)	0.001
HR (beats $\times$ min)*		80 (70–94)		75 (67–85)	0.003
RR (breath $\times$ min)*		20 (18–22)		18 (16–20)	0.000
Killip I	59	31.2	199	100	0.000
Sinus rhythm	180	95.2	191	95.9	0.661
Atrial fibrillation	4	2.1	2	1.01	0.661
Anterior wall MI	135	71.4	86	43.2	0.000
Large MI in ECG**	71	37.5	62	31.1	0.184
T negative waves***	110	58.2	141	70.8	0.009
Reperfusion treatment	152	80.4	174	87.4	0.059
Reperfusion < 12 h	120	63.4	137	68.8	0.265
Fibrinolysis	79	41.8	80	40.2	0.749
PCI	96	50.7	116	58.2	0.13
TIMI 3 flow post PCI	71	75.5	103	88.7	0.060
Troponin > 10 times N.V.	122	66.3	92	47.1	0.002
Mitral regurgitation***	9	4.8	2	1.05	0.006
LVEF (%)*		40 (35–45)		50 (45–56)	0.000
Ischemic time for fibrinolysis (hours)*		4 (3–6)		3.3 (2.3–5.4)	0.080
Ischemic time for PCI (hours)*		9.3 (5–14)		7.5 (5–13)	0.155

ECG: electrocardiogram, HR: heart rate, LVEF: left ventricular ejection fraction, N.V.: normal value, PCI: percutaneous coronary intervention, RR: respiratory rate, SAP: systolic blood pressure.

\* Expressed in median (interquartile range).

\*\* Extensive anterior or infero-postero-lateral wall MI.

\*\*\* Post reperfusion treatment.

+++ Severe mitral regurgitation.

**Table 2** Uni and multivariate logistic regression analysis of heart failure predictors post STEMI.

	Univariate analysis			Multivariate analysis		
	OR	CI 95%	p value	OR	CI 95%	p value
Male sex	1.03	0.6–1.6	0.892	0.8	0.4–1.4	0.454
Age > 75 years	2.1	1.3–3.4	0.001	2.7	1.5–4.7	0.000
Anterior wall MI	3.2	2.1–5	0.000	3.5	2.2–5.6	0.000
T negative waves post reperfusion	0.5	0.3–0.8	0.009	0.5	0.3–0.9	0.027
Reperfusion < 24 h	0.78	0.4–1.2	0.318	0.9	0.5–1.6	0.909
Troponin > 10 times N.V.	1.6	1.2–2.2	0.001	1.5	1.1–2.1	0.005

MI: myocardial infarction, N.V.: normal value.

part to the inclusion of patients with non ST-segment elevation MI in the French study (with a lower incidence of HF in this sub-group patients). In addition, in our study, a largest number of patients were treated in national referral centers, which probably increased the number of more ill patients, with symptomatic HF since admission (68.8% versus 60.9% in the French study).<sup>13</sup>

HF and left ventricular systolic dysfunction (LVEF less than or equal to 40%) should not be considered as synonyms<sup>14</sup>


because many patients with LVSD may be asymptomatic (asymptomatic left ventricular dysfunction); in our study, this percentage reached 16.4% in group 1. Similarly, 30–50% of patients with HF do not have LVSD<sup>15,16</sup>; but in both cases the morbidity and mortality are increased.<sup>17</sup> In our study, up to 36.5% of patients presented HF symptoms with preserved LVEF (>40%).

Unlike some registries, where the female sex was more prone to develop HF in the context of a MI,<sup>18,19</sup> we did not

**Table 3** In-hospital treatment and discharge medication in both study groups.

	Group 1		Group 2		p value
	n	%	n	%	
<i>In-hospital</i>					
Inotropic medication	52	27.5	1	1.01	<0.001
Vasopressors	53	28.04	4	2	<0.001
IABP	10	5.2	0	0	0.001
Non-invasive ventilation	6	3.1	0	0	0.013
Mechanical ventilation	45	23.8	2	1.01	<0.001
<i>At discharge</i>					
Beta-blockers	124	83.7	168	84.8	0.787
ACEI/ARB	106	71.6	104	52.5	0.000
Diuretics	44	29.7	11	5.5	0.000
Spironolactone	45	30.4	8	4.04	0.000
Aspirin	148	100	198	100	
Clopidogrel	119	80.4	171	86.3	0.137
Ticagrelor	28	18.9	19	9.6	0.012
Statins	141	95.2	194	97.9	0.155

ACEI: angiotensin-converting enzyme inhibitors, ARB: angiotensin receptor blocker, IABP: intra-aortic balloon counterpulsation.

**Figure 1** Kaplan-Meier survival curves at 30 days in patients with HF (group 1) and without HF (group 2) post STEMI.**Table 4** Predictors of in-hospital and 30-day mortality in group 1.

	Multivariate analysis		
	OR	CI 95%	p value
Age > 75 years	8.3	2.2–31.4	0.002
Absence of T negative waves post reperfusion	11.3	2.7–46.7	0.001
Inotropic medication	10.1	1.5–66	0.016
Mechanical ventilation	1.3	0.2–6.7	0.726
Vasopressors	3	0.5–15.3	0.185
IABP	6.1	0.5–65.2	0.136

IABP: intra-aortic balloon counterpulsation.

find difference in the incidence of HF according to sex (OR 1.03 95%, CI 0.6–1.6,  $p=0.892$ ).

Regarding the incidence of symptomatic HF in the first 28 days after MI, some authors have found values of up to 22.4% of cases, more frequent in the elderly, women,

diabetics and hypertensive patients; its presence was associated with a longer hospital stay and a higher mortality rate at 1-year and 10 years (4% year and 24.6% 10 years).<sup>20</sup>

Rich et al. found that HF during myocardial infarction was present in 33% of people younger than 70 years old and in 56% of those older than 70 years.<sup>19</sup> Similar to our results where the highest incidence of HF was in population older than 75 years.

Steg et al. found that 46.2% of HF patients had an anterior wall infarction, compared with 33.6% in those without HF ( $p<0.0001$ ), as well as more Q waves on ECG, left bundle branch block and atrial fibrillation<sup>10</sup>; they also found that advanced age, high heart rate, diabetes and previous diuretic use were independent predictors of HF.<sup>10</sup> We also found that the anterior wall MI was related to more HF. Although there was a trend for higher incidence of HF in large infarcts (extensive anterior, infero-postero-lateral), it was not significant (unlike the definition of large infarction by troponin value >10 times the normal range).

The use of ACEI and beta-blockers early in the context of MI showed a decrease in mortality.<sup>21–25</sup> In PRIAMHO II study 55.9% of patients received beta-blockers and 45.1% ACEI at discharge, but in patients with HF (Killip > 1 or LVEF < 40%) only 25.4 received both drugs at discharge and had a mortality rate of 57.4% per year.<sup>26</sup> We found that the percentages of use of both drugs are above 70% in patients of group 1; this may be due to the fact that patients were treated in national teaching hospitals with a high rate of use of medication according to international guidelines. Some national reports,<sup>27</sup> observed that beta-blockers use in patients with HF at the time of decompensation is only 31.7%, which leads us to infer a discontinuation of its use after the MI.

The use of aldosterone inhibitors together with ACEI prevents left ventricular remodeling.<sup>28,29</sup> López de Sá et al.,<sup>30</sup> found that it was prescribed in 54.8% of patients with the indication for its use and it was found associated with greater survival at 30 days compared to untreated patients (88.3% and 77.7% respectively). We found that the use of



spironolactone in group 1 reached only 30%, although in patients with LVEF < 40% it was used in up to 45% of cases.

Many reports since last century, correlates post MI heart failure with higher 1-year mortality, reaching up to 40% (HF group) versus 9% (without HF).<sup>19,31</sup> The in-hospital mortality found by Steg et al.,<sup>10</sup> was 12% in patients with HF versus 2.9% without HF (OR 4.6, 95% CI: 3.8–5.4) lower than our study (20.6%). The higher mortality found by us, may be due to the higher average age and the lack of adequate reperfusion of the myocardium, evidenced by the lower percentage of negative T waves in the electrocardiogram after the application of reperfusion therapy.<sup>32</sup>

The Killip score at admission is a well-known predictor of short and long-term risk<sup>10,33</sup>; Vicent et al., found that in-hospital mortality increased according to the Killip class (1.5; 3.7; 16.7 and 36.7% for KK I, II, III and IV, respectively)<sup>32</sup> similar to our study, although in cases with Killip IV our mortality was notoriously higher (61.1 versus 36.7%).

The use of inotropes in patients with acute heart failure has been related to higher mortality in the ADHERE study<sup>34</sup>; in the multivariate analysis, in our study, it was associated with higher in-hospital mortality, although not statistically significant, unlike the use of noradrenaline, which indicates that our patients could be in more severe states of HF (cardiogenic shock) with consequent higher mortality.

The importance of adequate and timely myocardial reperfusion is vital to reduce mortality and the development of HF; Comparing with the SwedeHeart registry<sup>35</sup> that found reperfusion rates greater than 80%, our reperfusion rate in the registry was only 67% in the first 12 h of the infarction,<sup>11</sup> (successful in less than 50% of fibrinolysis and up to 80% of primary PCI) which explains the high percentage of patients in group 1. We did not find differences in ischemic time to reperfusion in both groups as long as the reperfusion has been done in the first 12 h of symptoms onset.

## Limitations

The present study has several limitations: being a registry, causality associations are not as strong as one would expect from a randomized study. A high percentage of patients were enrolled in the capital city and in teaching hospitals, which may include a bias in the degree of severity of the disease and the management of patients, so it could be unrepresentative of the reality of the country.

## Conclusions

Heart failure complicates almost 50% of patients with STEMI and is associated with higher in-hospital and 30-days mortality. Age greater than 75 years, anterior wall MI, troponin more than 10 times the normal value and the absence of negative T waves in the post-reperfusion ECG are independent factors for higher incidence of HF. Also age > 75 years and the absence of negative T waves are independent predictors for in-hospital and 30-day mortality.

## Funding

None declared.

## Conflict of interest

The authors declare no conflict of interest.

## Acknowledgment

The PERSTEMI investigators: Alejandro Vega, Patricia Ríos, Roberto Baltodano, Fernando Villanueva, Alexander Montesinos, Jorge Martos, John Zevallos, David Miranda, Jorge Gutiérrez, José Carasas, Alexander Pecho, Sandra Negrón, Henry Anchante, Nassip Llerena, Germán Yábar, Javier Chumbe, Sara Ramírez, Marco Lazo, Jorge Sotomayor y Marco López.

## References

1. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. *Circulation*. 1998;97:282–9.
2. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. *Lancet*. 1986;1:397–402.
3. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. *Lancet*. 1990;336:65–71.
4. Rott D, Behar S, Gottlieb S, et al. Usefulness of the Killip classification for early risk stratification of patients with acute myocardial infarction in the 1990s compared with those treated in the 1980s. *Am J Cardiol*. 1997;80:859–64.
5. Wu A, Parsons L, Every N, et al. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. A Report From the Second National Registry of Myocardial Infarction (NRM-2). *J Am Coll Cardiol*. 2002;40:1389–94.
6. Miller WL, Wright RS, Grill JP, et al. Improved survival after acute myocardial infarction in patients with advanced Killip class. *Clin Cardiol*. 2000;23:751–8.
7. Gheorghiade M, Fonarow G. Management of post-myocardial infarction patients with left ventricular systolic dysfunction. *Am J Med*. 2007;120:109–20.
8. Steg G, James S, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *Eur Heart J*. 2012;33:2569–619.
9. Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. *JAMA*. 2001;286:1356–9.
10. Steg PG, Dabbous O, Feldmant L, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes observations From the Global Registry of Acute Coronary Events (GRACE). *Circulation*. 2004;109:494–9.
11. Chacón-Díaz M, Vega A, Aráoz O, et al. Características epidemiológicas del infarto de miocardio con elevación del segmento ST en Perú: resultados del Peruvian Registry of ST-segment Elevation Myocardial Infarction (PERSTEMI). *Arch Cardiol Mex*. 2018;88:403–12.
12. McKee PA, Castelli WP, McNamara P, et al. The natural history of congestive heart failure: the Framingham study. *N Engl J Med*. 1971;285:1441–8.
13. Juillière Y, Cambou J, Bataille V, et al. Heart failure in acute myocardial infarction: a comparison between patients with or

- without heart failure criteria from the FAST –MI registry. *Rev Esp Cardiol.* 2012;65:326–33.
14. Kober L, Torp-Pedersen C, Jorgensen S, et al. Changes in absolute and relative importance in the prognostic value of left ventricular systolic function and congestive heart failure after acute myocardial infarction. *Am J Cardiol.* 1998;81:1292–7.
  15. Moller JE, Brendorp B, Ottesen M, et al. Congestive heart failure with preserved left ventricular systolic function after acute myocardial infarction: clinical and prognostic implications. *Eur J Heart Fail.* 2003;5:811–9.
  16. Hellermann JP, Jacobsen SJ, Reeder GS, et al. Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community. *Am Heart J.* 2003;145:742–8.
  17. Cleland J, Torabi A, Khan N. Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. *Heart.* 2005;91 Suppl. II, ii7-ii13.
  18. Weaver W, White H, Wilco R, et al. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. *JAMA.* 1996;275:777–82.
  19. Rich M, Bosner M, Chung M, et al. Is age an independent predictor of early and late mortality in patients with acute myocardial infarction? *Am J Med.* 1992;92:7–13.
  20. Najafi F, Dobson A, Hobbs M, et al. Temporal trends in the frequency and longer-term outcome of heart failure complicating myocardial infarction. *Eur J Heart Fail.* 2007;9:879–85.
  21. GISSI -3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 – week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardio. *Lancet.* 1994;343:1115–22.
  22. The Capricorn investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet.* 2001;357:1385–90.
  23. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med.* 1992;327:669–77.
  24. AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. *Lancet.* 1993;342:821–8.
  25. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Trandolapril Cardiac Evaluation. TRACE Study Group. *Lancet.* 1999;354:9–12.
  26. Aros F, Loma-Orsio A, Vila J, et al. Efecto de la asociación de bloqueadores beta e inhibidores de la enzima de conversión en la supervivencia al año tras un infarto agudo de miocardio. Resultados del registro PRIAMHO II. *Rev Esp Cardiol.* 2006;59:313–20.
  27. Pariona M, Segura PA, Padilla M, et al. Características clínico epidemiológicas de la insuficiencia cardíaca aguda en un hospital terciario de Lima, Perú. *Rev Peru Med Exp Salud Publica.* 2017;34:655–9.
  28. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. *Circulation.* 2003;107:2559–65.
  29. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med.* 2003;348:1309–21.
  30. López-de-Sá E, Martínez A, Anguita M, et al. Uso de antagonistas de los receptores de aldosterona tras el infarto de miocardio. Datos del registro REICIAM. *Rev Esp Cardiol.* 2011;64:981–7.
  31. Wolk M, Scheidt S, Killip T. Heart failure complicating acute myocardial infarction. *Circulation.* 1972;45:1125–38.
  32. Vicent L, Velasquez J, Valero M, et al. Predictors of high Killip class after ST segment elevation myocardial infarction in the era of primary reperfusion. *Int J Cardiol.* 2017;248:46–50.
  33. Parakh K, Thombs B, Bhat U, et al. Long-term significance of killip class and left ventricular systolic dysfunction. *Am J Med.* 2008;121:1015–8.
  34. Abraham WT, Adams KF, Fonarow GC, et al. The ADHERE Scientific Advisory Committee and Investigators and ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). *J Am Coll Cardiol.* 2005;46:57–64.
  35. Szummer K. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. *Eur Heart J.* 2017;38:3050–65.